Secondary Outcome(s)
|
Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)
[Time Frame: Baseline up to 24 weeks]
|
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment
[Time Frame: 8, 12 and 16 weeks (number of active T2 lesions during the washout period only)]
|
Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group
[Time Frame: Baseline to week 16 and week 32]
|
Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion
[Time Frame: 8 weeks and 24 weeks]
|
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period
[Time Frame: Baseline to maximum of 16 weeks]
|
Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment
[Time Frame: Number of active T2 lesions during 8 wks of fingolimod treatment]
|
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment
[Time Frame: Baseline to maximum of 16 weeks]
|